Korean biotech eyes deals, partnerships at BIO 2026
Summary
Korean biotech companies are using BIO 2026 to pursue global partnerships and commercial deals. Samsung Biologics is showcasing its CDMO capabilities and Rockville plant acquisition, while Celltrion is promoting biosimilars, AI-driven research, and next-generation drug platforms. SK Biopharmaceuticals is highlighting AI-based drug discovery and digital R&D, and Lotte Biologics is presenting its new plant and digital manufacturing capabilities. KoreaBio is also promoting 51 companies through a country pavilion and an official session on Korea’s biotech industry.
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected